Miscellaneous antibacterial drugs

Side Effects of Drugs Annual

Volumn 35, Issue , 2014, Pages 463-481

  Choi, Taylor A ^a  

^a NONE

Author keywords

Adverse reactions; Amikacin; Aminoglycosides; Azithromycin; Ciprofloxacin; Clarithromycin; Clindamycin; Co trimoxazole; Colistin; Daptomycin; Erythromycin; Fluoroquinolones; Fosfomycin; Fusidic acid; Gentamicin; Glycopeptides; Ketolides; Levofloxacin; Lincosamides; Linezolid; Macrolides; Moxifloxacin; Nitrofurantoin; Ofloxacin; Oritavancin; Oxazolidinones; Polymyxins; Pristinamycin; Solithromycin; Spiramycin; Streptogramins; Sulfonamides; Teicoplanin; Telavancin; Telithromycin; Tobramycin; Torezolid; Trimethoprim; Vancomycin

Indexed keywords

EID: 84895085795     PISSN: 03786080     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-62635-6.00026-7     Document Type: Chapter

References (120)

1. Tabuchi K., Nishimura B., Nakamagoe M., Hayashi K., Nakayama M., Hara A. Ototoxicity: mechanisms of cochlear impairment and its prevention. Curr Med Chem 2011, 18(31):4866-4871.
2. Reiter R.J., Tan D.X., Korkmaz A., Fuentes-Broto L. Drug-mediated ototoxicity and tinnitus: alleviation with melatonin. J Physiol Pharmacol 2011, 62(2):151-157.
3. Sturdy A., Goodman A., Jose R.J., Loyse A., O'Donoghue M., Kon O.M., Dedicoat M.J., Harrison T.S., John L., Lipman M., Cooke G.S. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother 2011, 66(8):1815-1820.
4. Guan M. Mitochondrial 12S rRNA mutations associated with aminoglycoside ototoxicity. Mitochondrion 2011, 11(2):237-245.
5. Meza G., Torres-Ruiz N.M., Tirado-Guiterrez C., Aguilera P. mtDNA mutations, hearing loss and aminoglycoside treatment in Mexicans. Braz J Otorhinolaryngol 2011, 77(5):573-576.
6. Abdel-Hady E., El Hamamsy M., Hedaya M., Awad H. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis. J Clin Pharm Ther 2011, 36(1):45-52.
7. Gálvez R.L.C., Cornejo R., Kosche J., Romero C., Tobar E., Illanes V., Llanos O., Castro J. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents 2011, 38(2):146-151.
8. Murray M.P., Govan J.R., Doherty C.J., Simpson A.J., Wilkinson T.S., Chalmers J.D., Greening A.P., Haslett C., Hill A.T. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011, 183(4):491-499.
9. Shirodkar A.R., Pathengay A., Flynn H.W. Intravitreal gentamicin-induced macular infarction: SD-OCT features. Ophthalmic Surg Lasers Imaging 2011, 42:e67-e70.
10. Cooper A.C., Commers A.R., Finkelstein M., Lipnik P.G., Tollefson L.M., Wilcox R.A., Hoff D.S. Otoacoustic emission screen results in critically ill neonates who received gentamicin in the first week of life. Pharmacotherapy 2011, 31(7):649-657.
11. Pullens B., van Benthem P.P. Intratympanic gentamicin for Méni[U+0450]re's disease or syndrome. Cochrane Database Syst Rev 2011, 3:CD008234.
12. Tang R.K., Tse R.K. Acute renal failure after topical fortified gentamicin and vancomycin eyedrops. J Ocul Pharmacol Ther 2011, 27(4):411-413.
13. Ramnarain D., de Lange D.W., Meulenbelt J. Acute renal failure due to tobramycin intoxication during selective digestive tract decontamination. Intensive Care Med 2011, 37(8):1386-1387.
14. Konstan M.W.F.P., Kappler M., Chiron R., Higgins M., Brockhaus F., Zhang J., Angyalosi G., He E., Geller D.E. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EATER trial. J Cyst Fibros 2011, 10(1):54-61.
15. Torfoss D.S.B., Mollnes T.E., Høiby E.A., Holte H., Bjerner J., Bjøro T., Gaudernack G., Kvalheim G., Kvaløy S. The mild inflammatory response in febrile neutropenic lymphoma patients with low risk of complications is more pronounced in patients receiving tobramycin once daily compared with three times daily. Scand J Immunol 2011, 74(6):632-639.
16. Briasoluis A.A., Pierce W.J. QT prolongation and torsade de pointes induced by fluoroquinolones: infrequent side effects from commonly used medications. Cardiology 2011, 120(2):103-110.
17. Jones S.C., Sorbello O., Boucher R.M. Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review. Drug Saf 2011, 34(10):839-847.
18. Kulthanan K., Chularojanamontri L., Manapajon A., Dhana N., Jongjarearnprasert K. Cutaneous adverse reactions to fluoroquinolones. Dermatitis 2011, 22(3):155-160.
19. Vinh H.A.V., Anh N.D., Campbell J.I., Hoang N.V., Nga T.V., Nhu N.T., Minh P.V., Thuy C.T., Duy P.T., Phuong le T., Loan H.T., Chinh M.T., Thao N.T., Tham N.T., Mong B.L., Bay P.V., Day J.N., Dolecek C., Lan N.P., Diep T.S., Farrar J.J., Chau N.V., Wolbers M., Baker S. A multi-center randomized trial to assess the efficacy of gatifloxacin versus ciprofloxacin for the treatment of shigellosis in Vietnamese children. PLoS Negl Trop Dis 2011, 5(8):e1264.
20. Kaguelidou F., Turner M.A., Choonara I., Jacqz-Aigrain E. Ciprofloxacin use in neonates: a systematic review of the literature. Pediatr Infect Dis 2011, 30(2):e29-e37.
21. Sideri G., Kafetzis D.A., Vouloumanou E.K., Papadatos J.H., Papadimitriou M., Falagas M.E. Ciprofloxacin in critically ill children. Anaesth Intensive Care 2011, 39(4):635-639.
22. Denysenko L., Nicolson S.E. Cefoxitin and ciprofloxacin neurotoxicity and catatonia in a patient on hemodialysis. Psychosomatics 2011, 52(4):379-383.
23. Ahmed A.I., van der Heijden F.M., van den Berkmortel H., Kramers K. A man who wanted to commit suicide by hanging himself: an adverse effect of ciprofloxacin. Gen Hosp Psychiatry 2011, 33(1):82.e5-82.e7.
24. Anty R., Hastier P., Saint-Paul M.C., Tran A. Unusual evolution of ciprofloxacin-induced hepatitis revealing a possible link with IgG4-associated autoimmune hepatitis. Dig Liver Dis 2011, 43(11):922-923.
25. Alan C., Koçoǧlu H., Ersay A.R., Ertung Y., Kurt H.A. Unexpected severe hepatotoxicity of ciprofloxacine: two case reports. Drug Chem Toxicol 2011, 34(2):189-191.
26. Treggiari M.M., Retsch-Bogart G., Mayer-Hamblett N., Khan U., Kulich M., Kronmal R., Williams H., Hiatt P., Gibson R.L., Spencer T., Orenstein D., Chatfield B.A., Froh D.K., Burns J.L., Rosenfeld M., Ramsey B.W. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011, 165(9):847-856.
27. Salloum R., Liu C.Y., Weise A.M. Possible case of levofloxacin-induced thrombocytopenia. Am J Health Syst Pharm 2011, 68(1):43-46.
28. Titos-Arcos J.C., Hallal H., Robles M., Andrade R.J. Hepatitis colestasica aguda asociada a levofloxacino. [Acute cholestatic hepatitis associated with levofloxacin.]. Gastroenterol Hepatol 2011, 34(5):369-370.
29. Ben Fredj N., Aouam K., Chaabane A., Braham D., Boughattas N.A. Fixed drug eruption: levofloxacin, another culprit drug. J Clin Pharmacol 2012, 52(5):775-777.
30. Fernández Arenas O., López Lunar E., Gutiérrez García M., Hidalgo Correas F.J., García Díaz B. Sindrome de Stevens-Johnson inducido por levofloxacino. [Levofloxacin-related Stevens-Johnson syndrome.]. Farm Hosp 2012, 36(1):53-55.
31. Esparza E.M., Takeshita J., George E. Lymphomatoid hypersensitivity reaction to levofloxacin during autologous stem cell transplantation: a potential diagnostic pitfall in patients treated for lymphoma or leukemia. J Cutan Pathol 2011, 38(1):33-37.
32. Kato A., Ishigaki S., Yasuda H. Levofloxacin-associated Achilles tendinitis in a patient with chronic kidney disease stage 5. Clin Exp Nephrol 2011, 15(2):318-319.
33. Turker T., Kutz J.E. Can oral levofloxacin cause of flexor digitorum profundus rupture?. Med Hypotheses 2011, 77(4):696-697.
34. Join-Lambert O., Coignard H., Jais J.P., Guet-Revillet H., Poirée S., Fraitag S., Jullien V., Ribadeau-Dumas F., Th'ze J., Le Guern A.S., Behillil S., Lefl'che A., Berche P., Consigny P.H., Lortholary O., Nassif X., Nassif A. Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology 2011, 222(1):49-58.
35. Pranger A.D., van Altena R., Aarnoutse R.E., van Soolingen D., Uges D.R.A., Kosterink J.G.W., van der Werf T.S., Alffenaar J.W. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J 2011, 38(4):888-894.
36. Gyssens I.C., Dryden M., Kujath P., Nathwani D., Schaper N., Hampel B., Reimnitz P., Alder J., Arvis P. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. J Antimicrob Chemother 2011, 66(11):2632-2642.
37. Baas T., Graefe K., Khawaja A., Doessel O. Investigation of parameters highlighting drug induced small changes of the T-wave's morphology for drug safety studies. Conf Proc IEEE Eng Med Biol Soc 2011, 2011:3796-3799.
38. Tiryakioǧlu S.K., Tiryakioǧlu O., Aktürk F., Mehmetoǧlu E., Kumbay E. Moxifloxacin-dependent torsades de pointes. Anadolu Kardiyol Derg 2011, 11(6):560-562.
39. Tasleem H., Viswanathan R. Moxifloxacin-induced delirium with hallucinations. Psychosomatics 2011, 52(5):472-474.
40. Yamamoto T., Hiraoka T., Oshika T. Time course of changes in functional visual acuity and ocular wavefront aberration after instillation of ofloxacin gel-forming ophthalmic solution. Nihon Ganka Gakkai Zasshi 2011, 115(12):1094-1100.
41. Dunbar L.M., Milata J., McClure T., Wasilewski M.M. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob Agents Chemother 2011, 55(7):3476-3484.
42. Hsiao S.H., Chou C.H., Lin W.L., Lee E.J., Liao L.H., Chang H.J., Yeh P.Y., Lin C.Y., Wu T.J. High risk of cross-reactivity between vancomycin and sequential teicoplanin therapy. J Clin Pharm Ther 2012, 37(3):296-300.
43. Ochi H., Wada K., Okada H., Kohara N., Fujita T., Toda K., Sakamoto M., Seguchi O., Murata Y., Yanase M., Nakatani T. The persistence of drug-induced fever by teicoplanin-a case report. Int J Clin Pharmacol Ther 2011, 49(5):339-343.
44. Ueda T., Takesue Y., Nakajima K., Ichki K., Wada Y., Tsuchida T., Takahashi Y., Ishihara M., Tatsumi S., Kimura T., Ikeuchi H., Uchino M. Evaluation of teicoplanin dosing designs to achieve a new target trough concentration. J Infect Chemother 2012, 18(3):296-302.
45. Turrentine J.E., Dharamsi J.W., Miedler J.D., Pandya A.G. Acute generalized exanthematous pustulosis (AGEP) caused by telavancin. J Am Acad Dermatol 2011, 65(3):e100-e101.
46. Shilling A., Neuner E., Rehm S.J. Vancomyin: a 50-something-year-old antibiotic we still don't understand. Cleve Clin J Med 2011, 78(7):465-471.
47. Lomaestro B.M. Vancomycin dosing and monitoring 2 years after the guidelines. Expert Rev Anti Infect Ther 2011, 9(6):657-667.
48. Das M.K., Pathengay A., Shah G.Y., Koday N.K. Vancomycin-resistant coagulase negative Staphylococcus endophthalmitis following cataract surgery. J Cataract Refract Surg 2011, 37(10):1908-1909.
49. Anand A., Chauhan H.K. Piperacillin and vancomycin induced severe thrombocytopenia in a hospitalized patient. Platelets 2011, 22(4):294-301.
50. Duff J.M., Moreb J.S., Muwalla F. Severe neutropenia following a prolonged course of vancomycin that progressed to agranulocytosis with drug reexposure. Ann Pharmacother 2012, 46(1):e1.
51. Black E., Lau T.T., Ensom M.H. Vancomycin-induced neutropenia: is it dose- or duration-related?. Ann Pharmacother 2011, 45(5):629-638.
52. Chen Y., Yang X.Y., Zeckel M., Killian C., Hornbuckle K., Regev A., Voss G. Risk of hepatic events in patients treated with vancomycin in clinical studies: a systematic review and meta-analysis. Drug Saf 2011, 34(1):73-82.
53. Gupta A., Biyani M., Khaira A. Vancomycin nephrotoxicity: myths and facts. Neth J Med 2011, 69(9):379-383.
54. Wong-Beringer A., Joo J., Tse E., Beringer P. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2011, 37(2):95-101.
55. Rodriguez C.O., Alvarez L.F., Gonzalez Perez M.I., Sirvent J.M., Garcia S.M. Impact of administration of vancomycin or linezolid to critically ill patients with impaired renal function. Eur J Clin Microbiol Infect Dis 2011, 30(5):635-643.
56. Rao S., Kupfer Y., Pagala M., Chapnick E., Tessler S. Systemic absorption of oral vancomycin in patients with Clostridium difficile infection. Scand J Infect Dis 2011, 43(5):386-388.
57. Htike N.K., Santoro J., Gilbert B., Elfenbein I.B., Teehan G. Biopsy-proven vancomycin-associated interstitial nephritis and acute tubular necrosis. Clin Exp Nephrol 2012, 16(2):320-324.
58. van Maarseveen E.M., Man W.H., Touw D.J., Bouma A.W., van Zanten A.R. Continuous and intermittent infusion of vancomycin equally effective: review of the literature. Ned Tijdschr Geneeskd 2011, 1555(42):A2667.
59. O'Brien M., Shah A., Allen H.B. A pentad of vancomycin reactions. Skinmed 2011, 9(4):225-229.
60. Bauters T., Claus B., Schelstraete P., Robays H., Benoit Y., Dhooge C. Vancomycin-induced red man syndrome in pediatric oncology: still an issue?. Int J Clin Pharm 2012, 34(1):13-16.
61. Freitas C., Rodrigeus A., Carvalho M.J., Cabrita A. Chemical peritonitis in a patient treated with icodextrin and intraperitoneal vancomycin. Nefrolgia 2011, 31(5):625-626.
62. Cataldo M.A., Tacconelli E., Grilli E., Pea F., Petrosillo N. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 2012, 67(1):12-24.
63. Gupta M., Durand M.L., Sobrin L. Vancomycin resistance in ocular infections. Int J Ophthalmol Clin 2011, 51(4):167-181.
64. Teo J.W., Krishnan P., Jureen R., Lin R.T. Detection of an unusual van genotype in a vancomycin-resistant Enterococcus faecium hospital isolate. J Clin Microbiol 2011, 49(12):4297-4298.
65. Theuretzbacher U. Resistance drives antibacterial drug development. Curr Opin Pharmacol 2011, 11(5):433-438.
66. Still J.G., Schranz J., Degenhardt T.P., Scott D., Fernandes P., Gutierrez M.J., Clark K. Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrob Agents Chemother 2011, 55(5):1997-2003.
67. Andrade R.J., Tulkens P.M. Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother 2011, 66(7):1431-1446.
68. Wagenvoort G.H., van Mook W.N., Bodelier A.G. Clindamycin-induced esophageal ulceration. Endoscopy 2011, 43(Suppl 2):E383.
69. Lamont R.F., Nhan-Chang C.L., Sobel J.D., Workowski K., Conde-Agudelo A., Romero R. Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol 2011, 205(3):177-190.
70. Ceschi A., Von Dechend M., Krause M., Kengelbacher M., Stuerer A. Acute laryngotracheitis after accidental aspiration of clindamycin. Q J Med 2011, 104(7):609-611.
71. Lehavi A., Sandler A., Netzer A., Katz Y.S. Vascular injury following accidental intra-arterial injection of clindamycin: adverse drug reaction report. Minerva Anestesiol 2011, 77(4):468-469.
72. Southern K.W., Barker P.M., Solis-Moya A., Patel L. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2011, 7(12):CD002203.
73. Cai Y., Chai D., Wang R., Bai N., Liang B.B., Liu Y. Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. J Antimicrob Chemother 2011, 66(5):968-978.
74. Farooq O., Memon Z., Stojanovski S.D., Faden H.S. Azithromycin-induced agitation and choreoathetosis. Pediatr Neurol 2011, 44(4):311-313.
75. Li H., Zhou Y., Fan F., Zhang Y., Li X., Yu H., Zhao L., Yi X., He G., Fujita J., Jiang D. Effect of azithromycin on patients with diffuse panbronchiolitis: retrospective study of 51 cases. Intern Med 2011, 50(16):1663-1669.
76. Ayele B., Gebre T., House J.I., Zhou Z., McCulloch C.E., Porco T.C., Gaynor B.D., Emerson P.M., Lietman T.M., Keenan J.D. Adverse events after mass azithromycin treatments for trachoma in Ethiopia. Am J Trop Med Hyg 2011, 85(2):291-294.
77. Liu P., Fang A.F., LaBadie R.R., Crownover P.H., Arguedas A.G. Comparison of azithromycin pharmacokinetics following single oral doses of extended-release and immediate-release formulations in children with acute otitis media. Antimicrob Agents Chemother 2011, 55(11):5022-5026.
78. Baranowksi W.J. Clarithromycin-induced hypersomnia in children. Int J Clin Pharmacol Ther 2011, 49(5):297-299.
79. Hajiiannou J.K., Florou V., Kousoulis P., Fragkos M., Moshovakis E. Clarithromycin induced reversible sensorineural hearing loss. B-ENT 2011, 7(2):127-130.
80. Trzebiatowska I., Barwina M., Waldman W., Sein Anand J. Psychoza spowodowana terapia klarytromycyna-opis przypadku. [Psychosis caused by the treatment with clarithromycin-a case report.]. Przegl Lek 2011, 68(8):560-561.
81. Bandettini di Poggio M., Anfosso S., Audenino D., Primavera A. Clarithromycin-induced neurotoxicity in adults. J Clin Neurosci 2011, 18(3):313-318.
82. Sohail M.A., Nasir J., Ikram U., Genese T. Serum sickness-like reaction with clarithromycin. J Hosp Med 2011, 6(4):231-232.
83. De Francesco V., Giorgio F., Ierardi E., Zotti M., Neri M., Milano A., Varassano V., Luzza F., Suraci E., Marmo R., Marone A., Manta R., Mirante V.G., de Matthaeis M., Pedroni A., Manes G., Pallotta S., Usai P., Liggi M., Gatto G., Peri V., Sacco R., Bresci G., Monica F., Hassan C., Zullo A. Primary clarithromycin resistance in Helicobacter pylori: the multicentric Italian clarithromycin resistance observational (MICRO) study. J Gastrointestin Liver Dis 2011, 20(3):235-239.
84. Liukas A., Hagelberg N.M., Kuusniemi K., Neuvonen P.J., Olkkola K.T. Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers. J Clin Psychopharmacol 2011, 31(3):302-308.
85. Franke R.M., Lancaster C.S., Peer C.J., Gibson A.A., Kosloske A.M., Orwick S.J., Mathijssen R.H., Figg W.D., Baker S.D., Sparrelboom A. Effect of ABCC2 (MRP2) transport function on erythromycin metabolism. Clin Pharmacol Ther 2011, 89(5):693-701.
86. Hussein R., El-Halabi M., Ghaith O., Jurdi N., Azar C., Mansour N., Sharara Al Severe hepatotoxicity associated with the combination of spiramycin plus metronidazole. Arab J Gastroenterol 2011, 12(1):44.
87. Kanji Z., Su V.C.H., Mainra R. Nitrofurantoin-induced pulmonary reaction involving respiratory symptoms: case report. Can J Hosp Pharm 2011, 64(5):362-365.
88. Hage P., El Hajje M.J. Nitrofurantoin-induced desquamative interstitial pneumonitis in a 7-year-old child. Pediatr Infect Dis 2011, 30(4):363.
89. Kiang T.K.L., Ford J.A., Yoshida E.M., Partovi N. Nitrofurantoin-associated lung and liver toxicity leading to liver transplantation in a middle-aged patient. Can J Hosp Pharm 2011, 64(4):262-270.
90. Shaw K.J., Barbachyn M.R. The oxazolidinones: past, present, and future. Ann N Y Acad Sci 2011, 1241:48-70.
91. Gould F.K. Linezolid: safety and efficacy in special populations. J Antimicrob Chemother 2011, 66(Suppl 4):iv3-iv6.
92. Garazzino S., Krzysztofiak A., Esposito S., Castagnola E., Plebani A., Galli L., Cellini M., Lipreri R., Scolfaro C., Bertaina C., Calitri C., Bozzola E., Lancella L., Quondamcarlo A., Bosis S., Pugni L., Losurdo G., Soresina A., De Gaudio M., Mariotti I., Mancini L., Gabiano C., Tovo P.A. Use of linezolid in infants and children: a retrospective multicentre study of the Italian Society for Paediatric Infectious Diseases. J Antimicrob Chemother 2011, 66(10):2393-2397.
93. Garazzino S., Tovo P.A. Clinical experience with linezolid in infants and children. J Antimicrob Chemother 2011, 66(Suppl 4):iv23-iv41.
94. Migliori G.B., Eker B., Richardson M.D., Sotgiu G., Zellweger J.P., Skrahina A., Ortmann J., Girardi E., Hoffmann H., Besozzi G., Bevilacqua N., Kirsten D., Centis R., Lange C., TBNET Study Group A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009, 34(2):387-393.
95. Villar M., Sotgiu G., D'Ambrosio L., Raymundo E., Fernandes L., Barbedo J., Diogo N., Lange C., Centis R., Migliori G.B. Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. Eur Respir J 2011, 38(3):730-733.
96. Simon A.M.E., Prelog M., Schenk W., Holzapfel J., Ebinger F., Klabunde-Cherwon A., Faber J., Groll A.H., Masjosthusmann K., Dohna-Schwake C., Beutel K., Dirkwinkel E., Lehrnbecher T., Ammann R.A., Müller A. Use of linezolid in neonatal and pediatric inpatient facilities-results of a retrospective multicenter survey. Eur J Clin Microbiol Infect Dis 2012, 31(7):1435-1442.
97. Nambiar S., Rellosa N., Wassel R.T., Borders-Hemphil V., Bradley J.S. Linezolid-associated peripheral and optic neuropathy in children. Pediatrics 2011, 127(6):1528-1532.
98. Cope T.E., McFarland R., Schaefer A. Rapid-onset, linezolid-induced lactic acidosis in MELAS. Mitochondrion 2011, 11(6):992-993.
99. Bodnar T., Starr K., Halter J.B. Linezolid-associated hypoglycemia in a 64-year-old man with type 2 diabetes. Am J Geriatr Pharmacother 2011, 9(1):88-92.
100. Carbajo T., Fenollosa M., Pons R., Calvo C. Lactic acidosis and linezolid-induced pancytopaenia. Nefrologia 2011, 31(1):107-108.
101. Marina V.P., Kasmani R. An uncommon side-effect of linezolid. Int Urol Nephrol 2012, 44(3):995-996.
102. Prokocimer P., Bien P., Surber J., Mehra P., DeAnda C., Bulitta J.B., Corey G.R. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob Agents Chemother 2011, 55(2):583-592.
103. Pogue J.M., Marchaim D., Kaye D., Kaye K.S. Revisiting "older" antimicrobials in the era of multidrug resistance. Pharmacotherapy 2011, 31(9):912-921.
104. Ko H., Jeon M.H., Choo E.J., Lee E.J., Kim T.H., Jun J.B., Gil H.W. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 2011, 117(3):c284-c288.
105. Patel J.A., Pacheco S.M., Postelnick M., Sutton S. Prolonged triple therapy for persistent multidrug-resistant Acinetobacter baumannii ventriculitis. Am J Health Syst Pharm 2011, 68(16):1527-1531.
106. Wood G.C. Aerosolized antibiotics for treating hospital-acquired and ventilator-associated pneumonia. Expert Rev Anti Infect Ther 2011, 9(11):993-1000.
107. Schmutz J.L., Trechot P. Pristinamycine et reaction anaphylactique. [Pristinamycin and anaphylactic reaction.]. Ann Dermatol Venereol 2011, 138(10):720.
108. Khalili H., Soudbakhsh A., Talasaz A.H. Severe hepatotoxicity and probably hepatorenal syndrome associated with sulfadiazine. Am J Health Syst Pharm 2011, 68(10):888-892.
109. Ho J.M., Juurlink D.N. Considerations when prescribing trimethoprim-sulfamethoxazole. CMAJ 2011, 183(16):1851-1858.
110. Repplinger M.D., Falk P.M. Trimethoprim-sulfamethoxazole-induced aseptic meningitis. Am J Emerg Med 2011, 29(2):242.e3-242.e5.
111. Caro J., Navarro-Hidalgo I., Civera M., Real J.T., Ascaso J.F. Severe, long-term hypoglycemia induced by co-trimoxazole in a patient with predisposing factors. Endocrinol Nutr 2012, 59(2):146-148.
112. Calderón-Ortiz R.C.-V.P., Muñiz-Ortega M., Lespier L., Córdova H. Life threatening hyperkalemia chronic kidney diseases patients treated with trimethoprim-sulfamethoxazole: a case series. Bol Asoc Med P R 2011, 103(3):15-17.
113. Jen S.P., Sharma R. Trimethoprim-sulphamethoxazole-associated rhabdomyolysis in an HIV-infected patient. INT J STD AIDS 2011, 22(7):411-412.
114. Mueller B.A., Crompton J.A., Donovan B.J., Yankalev S., Lamp K.C. Safety of daptomycin in patients receiving hemodialysis. Pharmacotherapy 2011, 31(7):665-672.
115. Colomba C., Rubino R., Siracusa L., Mazzola G., Titone L. Rhabdomyolysis associated with the co-administration of daptomycin and pegylated interferon alpha-2b and ribavirin in a patient with hepatitis C. J Antimicrob Chemother 2012, 67(1):249-250.
116. van Hal S.J., Paterson D.L., Gosbell I.B. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-näive patient-a review of the literature. Eur J Clin Microbiol Infect Dis 2011, 30(5):603-610.
117. Palacio F., Lewis J.S., Sadkowski L., Echevarria K., Jorgensen J.H. Breakthrough bacteremia and septic shock due to Streptococcus anginosus resistant to daptomycin in a patient receiving daptomycin therapy. Antimicrob Agents Chemother 2011, 55(7):3639-3640.
118. Gamboa P.M., Antepara J., Jauregui I., Urrutia I., Sanz M.L. Two patients with anaphylactic shock due to fosfomycin. Ann Allergy Asthma Immunol 2011, 106(3):260-261.
119. Craft J.C., Moriarty S.R., Clark K., Scott D., Degenhardt T.P., Still J.G., Corey G.R., Das A., Fernandes P. A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clin Infect Dis 2011, 52(Suppl 7):S520-S526.
120. Still J.G., Clark K., Degenhardt T.P., Scott D., Fernandes P., Gutierrez M.J. Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects. Clin Infect Dis 2011, 52(Suppl 7):S504-S512.